Actionable news
0
All posts from Actionable news
Actionable news in TKAI: TOKAI PHARMACEUTICALS Inc,

What's Wrong With Tokai Pharmaceuticals?

Summary

Tokai’s attempt at a Phase 3 trial is based on data from just 6 patients out of 87 in Phase 2, based on after-the-fact cherry picking of data.

Tokai dramatically changed its trial design between Phase 2 and Phase 3, and the FDA has already warned Tokai about problems with its trial design.

Insider selling has been rampant ahead of preliminary data in 2016.

Tokai just filed a massive $150 million S3 registration statement in order to raise money before Phase 3 results are known.

Expect 60-70% near-term downside in the stock.

Summary

Tokai Pharmaceuticals (NASDAQ:TKAI) is a one-product biotech company with a single drug in development...


More